Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of chronic respiratory diseases with significant unmet medical needs. If successfully developed and approved, Verona Pharma's product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. Ensifentrine met the primary endpoint in both ENHANCE-1 and ENHANCE-2 trials demonstrating statistically significant and clinically meaningful improvements in lung function. In addition, ensifentrine significantly reduced the rate of COPD exacerbations in ENHANCE-1 and ENHANCE-2. We are led by a management team with an established track record in the discovery, development and commercialization of respiratory therapies. Verona Pharma is listed on the Nasdaq Global Market in the United States under the ticker symbol VRNA. We are headquartered in London, UK, and have offices in Raleigh and Savannah in the US. For more information, please visit https://www.veronapharma.com.
解鎖市場時間軸與訊號動態
此公司進入各市場的次序 — 由最舊至最新
治療慢性阻塞性肺病新藥申請獲中國受理
治療慢性阻塞性肺病新藥申請獲中國受理
註冊以查看完整訊號動態
Verona Pharma 的國際擴張與競爭對手的比較
Verona Pharma你長條顯示所比較各公司之間的相對規模。
欄位5| 公司 | 市場 | 新市場 | 動能 | 活動 | 擴張評分 |
|---|---|---|---|---|---|
 Verona Pharma你 | 0 | 0 | 0% | 0 | 18 |
Medical Science Liaison
查看招聘California, United States · 上年
無進行中的廣告活動
註冊以追蹤此公司，並在發生變化時第一時間獲得提醒。
Nuance Pharma 的第三期 ENHANCE-CHINA 試驗評估霧化恩西芬特林治療 COPD，達到主要和次要終點，顯示顯著改善肺功能和降低急性加重率。
優銳醫藥的ENHANCE-CHINA試驗顯示恩司芬群在COPD治療中顯著改善肺功能、生活質量，並降低急性加重風險。計劃2025年下半年提交新藥申請。
優銳醫藥的ENHANCE-CHINA試驗顯示恩司芬群在COPD治療中顯著改善肺功能、生活質量，並降低急性加重風險。
解鎖已驗證電郵與直撥電話
免費 · 無需信用卡
關於 Verona Pharma 業務、市場及增長訊號的快速解答。
